Company Announcements

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London. 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 12: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

·      Resolution 13: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and

·      Resolution 14: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com

Certified copies of the document setting out the above resolutions passed at the 2019 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2019) there were 68,928,847 ordinary shares in issue, each carrying one vote per share.

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

-Ends-

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com